Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic virus-specific T lymphocytes R-MVST

A preparation of allogeneic T lymphocytes generated from partially human leukocyte antigen (HLA)-matched healthy donors or from the original allogeneic hematopoietic stem cell transplantation (HSCT) donor, ex-vivo expanded, and specifically reactive to viruses that may include adenovirus (AdV), cytomegalovirus (CMV), Epstein-Barr virus (EBV) and human polyomavirus type I (BKV), with potential antiviral activity. Upon administration, the allogeneic virus-specific T lymphocytes R-MVST may kill AdV, CMV, EBV and/or BKV-infected cells, and may prevent or reduce the severity of viral infections by these pathogens.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:R-MVST cells
rapidly-generated virus-specific T cells
Abbreviation:R-MVST
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search